03 June, 2017
The institutional investor owned 338,501 shares of the medical research company's stock after selling 542 shares during the period. The stock of Edwards Lifesciences Corp (NYSE:EW) has "Outperform" rating given on Wednesday, April 26 by RBC Capital Markets. After posting $0.94 EPS for the previous quarter, Edwards Lifesciences Corp's analysts now forecast -6.38 % negative EPS growth. The firm bought 3,565 shares of the medical research company's stock, valued at approximately $335,000. HAP Trading LLC bought a new position in Edwards Lifesciences Corp during the third quarter worth approximately $3,859,000. Municipal Employees Retirement System of MI increased its position in Edwards Lifesciences Corp by 0.3% in the third quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company's stock valued at $115,000 after buying an additional 500 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in Edwards Lifesciences Corp by 23.7% in the third quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company's stock worth $109,000 after buying an additional 41 shares during the last quarter. March Altus Capital Management LP boosted its position in Edwards Lifesciences Corp by 86.0% in the third quarter. Over the past 2 quarters, the stock is up 39.90%, compared with a gain of almost 25.73% for 3 months and about 6.60% for the past 30 days. Finally, Montag & Caldwell LLC boosted its position in Edwards Lifesciences Corp by 10.5% in the third quarter. About shares traded. Edwards Lifesciences Corp (NYSE:EW) has risen 15.41% since June 2, 2016 and is uptrending. The firm's 50-day moving average is $108.43 and its 200 day moving average is $96.19. Their 52-Week High and Low are noted here. With Edwards Lifesciences Corporation (NYSE:EW) shares passing the 70 level, the stock is now considered to be in overbought territory and ripe for a potential pullback. The medical research company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.12. Edwards Lifesciences Corp had a net margin of 19.22% and a return on equity of 25.00%. The company had revenue of $883.50 million for the quarter, compared to analyst estimates of $776.51 million. The business's quarterly revenue was up 26.7% compared to the same quarter a year ago.
Among 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 18 have Buy rating, 1 Sell and 6 Hold.
WARNING: This report was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another publication, it was illegally stolen and republished in violation of United States and worldwide trademark and copyright legislation. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/06/02/johnston-asset-management-llc-sells-542-shares-of-edwards-lifesciences-corp-ew.html.
The stock is expected to report revenue as high as $854.67M and as low as $792.7M per share. Finally, Stifel Nicolaus lifted their price objective on Edwards Lifesciences Corp from $114.00 to $118.00 and gave the stock a "buy" rating in a research report on Wednesday, April 26th. On a one to five ratings scale where 1.0 indicates a Strong Buy, 2.0 indicates a Buy, 3.0 a Hold, 4.0 a Sell and 5.0 a Stong Sell. Analysts have placed a $120.75 price target on Edwards Lifesciences Corporation, suggesting a 2.87% gain from recent close. The firm earned "Outperform" rating on Wednesday, April 27 by Cowen & Co. Zacks downgraded the shares of EW in report on Tuesday, September 22 to "Hold" rating. They noted that the move was a valuation call. The firm has "Buy" rating by Bank of America given on Wednesday, July 27. The stock was sold at an average price of $111.64, for a total value of $1,283,860.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The company was upgraded on Monday, October 19 by Wells Fargo. The disclosure for this sale can be found here. Municipal Employees Retirement System of MI now owns 6,700 shares of the medical research company's stock worth $808,000 after buying an additional 20 shares during the last quarter.
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve.
